TOI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TOI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Oncology Institute's total inventories for the quarter that ended in Dec. 2024 was $10.0 Mil. The Oncology Institute's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $10.1 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. The Oncology Institute's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-1.03.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. The Oncology Institute's Days Inventory for the three months ended in Dec. 2024 was 10.73.
Inventory Turnover measures how fast the company turns over its inventory within a year. The Oncology Institute's Inventory Turnover for the quarter that ended in Dec. 2024 was 8.50.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. The Oncology Institute's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.10.
The historical data trend for The Oncology Institute's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Total Inventories | Get a 7-Day Free Trial | 4.35 | 6.44 | 9.26 | 13.68 | 10.04 |
The Oncology Institute Quarterly Data | ||||||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Total Inventories | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
13.68 | 11.55 | 11.32 | 10.11 | 10.04 |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
The Oncology Institute (NAS:TOI) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
The Oncology Institute's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is
Net-Net Working Capital Per Share (Q: Dec. 2024 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (49.669 | + | 0.75 * 48.335 | + | 0.5 * 10.039 | - | 169.128 |
- | 0 | - | 0) | / | 75.737 | ||
= | -1.03 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
The Oncology Institute's Days Inventory for the three months ended in Dec. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2024 ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | 10.0725 | / | 85.631 | * | 365 / 4 | |
= | 10.73 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
The Oncology Institute's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Dec. 2024 ) | / | Average Total Inventories (Q: Dec. 2024 ) |
= | 85.631 | / | 10.0725 | |
= | 8.50 |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The Oncology Institute's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 10.0725 | / | 100.267 | |
= | 0.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of The Oncology Institute's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Brad Hively | director, officer: Chief Executive Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Havencrest Healthcare Partners, L.p. | 10 percent owner | 5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039 |
Mihir Shah | officer: Chief Financial Officer, other: Principal Financial Officer | C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801 |
Jeremy Castle | officer: Chief Operating Officer | 1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Richard A Barasch | director, officer: Executive Chairman | C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573 |
Matthew P Miller | officer: Chief Operating Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Daniel Virnich | officer: Chief Operating Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Yale Podnos | officer: Chief Medical Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Diona Simoneit | officer: Chief Accounting Officer, other: Principal Accounting Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Mohit Kaushal | director | 44 SOUTH BROADWAY, WHITE PLAINS NY 10601 |
Gabriel Ling | director | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Mark L Pacala | director | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Richy Agajanian | 10 percent owner | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Maeve O'meara | director | C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105 |
Toi Hc I, Llc | 10 percent owner | 2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 05-15-2024
By Marketwired • 05-22-2024
By Marketwired • 04-23-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 12-18-2024
By GuruFocus Research • 05-15-2024
By Marketwired • 03-04-2025
By GuruFocus Research • 03-27-2024
By Marketwired • 11-11-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.